



**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

				Complete if Known	
				Application Number	10/820,144.
				Filing Date	April 8, 2004
				First Named Inventor	Esther H. Chang
				Group Art Unit	1632
				Examiner Name	
Sheet	1	of	2	Attorney Docket Number	2444-116

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code <sup>2</sup> (if known)		
SL	AA	5,693,509		Cotten et al.	Dec. 12, 1997
	AB	5,962,311		Wickham et al.	Oct. 5, 1999
	AC	5,994,109		Woo et al.	Nov. 30, 1999
SL	AD	6,410,010		Zhang et al.	Jun 25, 2002

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>6</sup>
		Office <sup>3</sup> Code	Number <sup>4</sup>	Kind <sup>5</sup> (if known)			
SL	AE	WO	94/24299		Boehringer Ingelheim Int'l GmbH	Oct. 27, 1994	
	AF	WO	97/38723		Immusol Inc.	Oct. 23, 1997	
SL	AG	WO	98/40508		Barbara Sosnowski et al.	Sep. 17, 1998	

Examiner Signature

*SL when*

Date Considered

*4-25-2007*

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code.

<sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>NOV 22 2004</i>				Complete if Known	
				Application Number	10/820,144
				Filing Date	April 8, 2004
				First Named Inventor	Esther H. Chang
				Group Art Unit	1632
				Examiner Name	
Sheet	2	of	2	Attorney Docket Number	2444-116
<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			
<i>SM</i>	AH	CARDUCCI et al., <i>Renal, Bladder and Prostate Cancers: Gene Therapy; Diagnosi and Treatment of Genitourinary Malignancies</i> , 1996, Kluwer Academic Publishers, Boston.			
	AI	COOPER, <i>Oncogenes</i> , by Jones and Bartlett Publishers; ISBN 0-86720-136-3, 1990			
	AJ	DEONARAIN, "Ligand-targeted receptor-mediated vectors for gene delivery," <i>Expert Opinion on Therapeutics Patents</i> , GB, Ashley Publications, 8(1):53-69, January 1998.			
	AK	DOUGLAS et al., "Targeted adenoviral vectors for cancer gene therapy (Review)," <i>International Journal of Oncology</i> , 11:341-348, 1997			
	AL	ECK et al., <i>Goodman &amp; Gilma's The Pharmacological Basis of Therapeutics</i> , McGraw-Hill, New York, pp. 77-101, 1996			
	AM	FEIGELSON et al., "Genetic Susceptibility to Cancer from xogenous and Endogenous Exposures," <i>Journal of Cellular Biochemistry</i> , 255:15-22 (1996)			
	AN	GURA, T., <i>Science</i> , 278:1041-1042, 1997			
	AO	HULME, <i>Receptor-Ligand Interactions-A Practical Approach</i> , Oxford University Press, Walton Street, Oxford OX2 6DP, ISBN 0-19-963090-9			
	AP	MICHAEL et al., "Strategies to achieve targeted gene delivery via the receptor-mediated endocytosis pathway," <i>Gene Therapy</i> 1:223-232, 1994.			
	AQ	MILLER et al., "Targeted vectors for gene therapy," <i>FASEB Journal, U.S. Fed. of American Society for Experimental Biology</i> , 9(2): 190-1999, February 1, 1995.			
	AR	Report and Recommendations of the Panel to Assess the NIH Investment Research on Gene Therapy, 12/7/95			
	AS	STAVRIDIS et al., "Construction of Transferrin-Coated Liposomes for In Vivo Transport of Exogenous DNA to Bone Marrow Erythroblasts in Rabbits," given as a communication at the NATO Advanced Studies Institute Conf., Cape Sounioin Beach, Greece, June 20-July 1, 1983.			
	AT	STRYER, <i>Biochemistry</i> , 1995, pp. 7, 8, 33-40, 938-939			
	AU	VERMA et al., <i>Nature</i> , 389:239-242, 1997			
	AV	WAGNER et al., "Transferrin - polycation conjugates as carriers for DNA uptake into cells," <i>Proc. Natl. Acad. Sci. USA</i> 87:3410-3414, May 1990.			
<i>SM</i>	AW	XU, "Transferrin-Liposome-Mediated p53 Sensitization of Squamous Cell Carcinoma of the Head and Neck to Radiation <i>In Vitro</i> ," <i>Human Gene Therapy</i> , 8:467-475, March 1, 1997.			
Examiner Signature	<i>S. Chen</i>			Date Considered	<i>4-25-09</i>

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

				Complete if Known	
				Application Number	10/820,144
				Filing Date	April 8, 2004
				First Named Inventor	Esther H. Chang
				Group Art Unit	1632
				Examiner Name	
				Confirmation No.	6653
Sheet	1	of	4	Attorney Docket Number	2444-116

## **U.S. PATENT DOCUMENTS**

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code. <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

				Complete if Known	
				Application Number	10/820,144
				Filing Date	April 8, 2004
				First Named Inventor	Esther H. Chang
				Group Art Unit	1632
				Examiner Name	
				Confirmation No.	6653
Sheet	2	of	4	Attorney Docket Number	2444-116

## **FOREIGN PATENT DOCUMENTS**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code.

<sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

				<i>Complete if Known</i>	
				Application Number	10/820,144
				Filing Date	April 8, 2004
				First Named Inventor	Esther H. Chang
				Group Art Unit	1632
				Examiner Name	
				Confirmation No.	6653
Sheet	3	of	4	Attorney Docket Number	2444-116

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published		
	AH	CARLUCCI et al., Rental, Bladder and prostate cancers: gene therapy; Diagnosis and Treatment of Genitourinary Malignancies, 1996, Kluwer Academic Publishers. Boston.		T <sup>2</sup>
	AI	COOPER, Oncogenes, 1990 by Jones and Bartlett Publishers, ISBN 0-86720-136-3		
	AJ	DEONARAIN, "Ligand-targeted receptor-mediated vectors for gene delivery," Expert Opinion on Therapeutics Patents, GB, Ashley Publications, 8(1):53-69, January 1998.		
	AK	DOUGLAS et al., "Targeted adenoviral vectors for cancer gene therapy (Review)," International Journal of Oncology, 1997, pp. 341-348, vol. 11.		
	AL	ECK et al., Goodman & Gilman's The Pharmacological Basis of Therapeutics, McGraw-Hill, New York, 1996, pp. 77-101		
	AM	FEIGELSON et al., Genetic Susceptibility to Cancer from exogenous and Endogenous Exposures; Journal of Cellular Biochemistry, 1996, pp. 15-22, vol. 255		
	AN	GURA, T., "Systems for Identifying New Drugs Are Often Faulty," Science, November 7, 1997, pp. 1041-1042, vol. 278.		
	AO	HULME, Receptor-Ligand Interactions-A practical Approach; Oxford University Press, Walton Street, Oxford OX2 6DP, ISBN 0-19-963090-9.		
	AP	MICHAEL et al., "Strategies to achieve targeted gene delivery via the receptor-mediated endocytosis pathway," Gene Therapy 1:223-232, 1994.		
	AQ	MILLER et al., "Targeted vectors for gene therapy," FASEB Journal, U.S. Fed. of American Society for Experimental Biology, 9(2): 190-1999, February 1, 1995.		
	AR	Report and Recommendations of the Panel to Assess the NIH Investment Research on Gene Therapy. 12/7/1995.		
	AS	STAVRIDIS et al., "Construction of Transferrin-Coated Liposomes for In Vivo Transport of Exogenous DNA to Bone Marrow Erythroblasts in Rabbits," given as a communication at the NATO Advanced Studies Institute Conf., Cape Sounion Beach, Greece, June 20-July 1, 1983.		

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

				Complete if Known	
				Application Number	10/820,144
				Filing Date	April 8, 2004
				First Named Inventor	Esther H. Chang
				Group Art Unit	1632
				Examiner Name	
				Confirmation No.	6653
Sheet	4	of	4	Attorney Docket Number	2444-116

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**'Unique citation designation number.** **2****Applicant is to place a check mark here if English language Translation is attached**